Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most ...
Mechanistically, HM17321 is a Ucn2 analog enabling a non-GLP-1 approach aimed at improving body composition by selectively reducing adiposity while preserving muscle mass and function. Preclinical ...
Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...
Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
Ying Huang, Ph.D., is the Chief Executive Officer and Board Director of K2 Therapeutics, and Strategic Advisor, APAC at MPM BioImpact. He brings over 9 years of experience in research and development ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's ...
From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated ...
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech ...
A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results